AxoGen (NASDAQ:AXGN - Free Report) had its target price raised by Canaccord Genuity Group from $18.00 to $22.00 in a report published on Monday,Benzinga reports. The firm currently has a buy rating on the medical equipment provider's stock.
Separately, StockNews.com upgraded shares of AxoGen from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th.
Check Out Our Latest Stock Analysis on AxoGen
AxoGen Stock Down 2.9 %
NASDAQ AXGN traded down $0.55 during trading hours on Monday, hitting $18.33. The company had a trading volume of 308,560 shares, compared to its average volume of 528,798. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The firm's 50 day moving average is $16.52 and its 200 day moving average is $14.01. The company has a market capitalization of $806.67 million, a price-to-earnings ratio of -57.28 and a beta of 1.00. AxoGen has a fifty-two week low of $5.55 and a fifty-two week high of $19.18.
Hedge Funds Weigh In On AxoGen
Hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC lifted its stake in AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock valued at $29,000 after buying an additional 2,076 shares during the last quarter. R Squared Ltd acquired a new position in shares of AxoGen during the fourth quarter valued at $30,000. US Bancorp DE acquired a new position in shares of AxoGen during the fourth quarter valued at $30,000. nVerses Capital LLC bought a new position in AxoGen during the third quarter valued at about $56,000. Finally, Oppenheimer & Co. Inc. bought a new position in AxoGen during the third quarter valued at about $156,000. Institutional investors and hedge funds own 80.29% of the company's stock.
About AxoGen
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Further Reading
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
